Intellia Therapeutics Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Intellia Therapeutics (NTLA) Misses Q1 EPS by 3c, Revenues Miss
May 6, 2021 7:40 AM EDTIntellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.69), $0.03 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $6.45 million versus the consensus estimate of $9.86 million.
Intellia continues to build momentum as we progress our full-spectrum pipeline towards key upcoming milestones... More
